A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination with Other Anticancer Agents in Participants with Solid Tumors (eVOLVE-01)
Fase: Phase II-III clinical trials
Struttura Principale: Oncologia Medica Toraco-Polmonare
Farmaco: Volrustomig
Chemotherapy (Carboplatin an Pemetrexed)
Patologie: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
PI: Dott. Giuseppe Lo Russo
Participants will be randomized in a 1:1 ratio to one of the following intervention arms:
- Arm 1A: Volrustomig + Carboplatin + Pemetrexed (first 4 cycles), then maintenance with Volrustomig 500 mg + Pemetrexed
- Arm 1B: Volrustomig + Carboplatin + Pemetrexed (first 4 cycles), then maintenance with Volrustomig 250 mg + Pemetrexed
Last update: 20/05/2025